Session Information
Date: Thursday, June 23, 2016
Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: This study aims to analyse the elemental profiles in the cerebrospinal fluid (CSF) of patients with idiopathic Parkinson´s disease (PD) and age-matched control patients in order to identify biomarkers for the early diagnosis and assessment of disease progression in PD.
Background: Idiopathic Parkinson’s disease (PD) is often difficult to differentiate from atypical or secondary parkinsonism especially in the early stages of the disease. At the same time, there are no reliable (bio)-markers for early diagnosis or for disease progression. A number of elements have been attributed particular roles in the pathogenesis of PD. For example, transition metals, such as iron, copper and manganese are known to promote alpha-synuclein aggregation or induce oxidative stress. Due to its close interaction with the brain parenchyma, CSF is able to reflect pathophysiological alterations occurring in neurodegeneration.
Methods: Patients with the clinical diagnosis of PD and atypical parkinsonism (MSA, CBD, PSP, LBD) as well as age-matched controls were included. The protocol contains two identical examinations within one year including medical history taking and clinical examination, cognitive screening, olfactory testing, routine blood tests, electrophysiology and substantia nigra ultrasound. CSF is collected at both time points. For detection of elemental profiles, the CSF samples were subjected to inductively coupled plasma-mass spectrometry (ICP-MS) allowing for the detection of >30 different elements at a detection limit of several ng/l.
Results: CSF samples of patients with PD (n= 75), atypical parkinsonism (n= 31) and age-matched controls (n= 92) have been obtained. Preliminary analyses of CSF demonstrated the successful resolution of > 30 single elements. After completion of ICP-MS analyses, elemental profiles will be correlated to clinical data to identify specific biomarker constellations.
Conclusions: Our study systematically assesses the elemental profiles in the CSF and may thus contribute to the identification of a biomarker profile to improve the diagnosis of PD and related disorders.
To cite this abstract in AMA style:
F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor. Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/elemental-profiles-as-biomarkers-for-diagnosis-and-disease-progression-of-parkinsons-disease/. Accessed May 17, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/elemental-profiles-as-biomarkers-for-diagnosis-and-disease-progression-of-parkinsons-disease/